UPDATED: Storm on the CAR-T field – three patients die in Phase II Explore A CAR-T program in Phase II trials (from Juno Therapeutics) was suspended by the FDA after three deaths, which could be treatment-related. How will this influence the field, given that most CAR-T Biotechs share the same target?

Read More »